Toggle light / dark theme

All this seems to indicate that the robotics industry isn’t going away anytime soon. If anything, the fact that investors are being more critical with their investments, paying more attention to market forces than to visionary-led promises means we’re entering a reality-driven age of investing in AI. The trouble is that this reality phase seems to be limited (so far) to the robotics industry. Tech companies in other corners of AI are still being wooed by investors with deep pockets and more patience than they have for robotics. Will the investments continue at the amounts and valuations currently supporting the industry? Or will these investors also be dragged down to earth by market and competitive realities? All that still remains to be seen. The hope is that the investment does continue, because after all, the quest for the intelligent machine has yet to be fully realized.


This is particularly perplexing since many AI companies are flush with cash and raising money at increasingly eye-watering levels and valuations. How could it be that these robotics firms, run and operated by some of the most celebrated people in the AI industry could be failing when seemingly less-compelling solutions such as process automation tools and facial recognition applications are raising billions of dollars? Is robotics really that hard or is there something else going on in the industry?

Read more

The history of human evolution has been rewritten after scientists discovered that Europe was the birthplace of mankind, not Africa.

Currently, most experts believe that our human lineage split from apes around seven million years ago in central Africa, where hominids remained for the next five million years before venturing further afield.

But two fossils of an ape-like creature which had human-like teeth have been found in Bulgaria and Greece, dating to 7.2 million years ago.

Read more

TRENTON, N.J. (AP) — U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet that is 10 times more powerful than Fentanyl and 1,000 times more potent than morphine.

The drug called Dsuvia was developed as an alternative to IV painkillers used in hospitals.

The decision by the Food and Drug Administration came over objections from critics who fear the pill will be abused. In a lengthy statement, FDA Commissioner Scott Gottlieb said there will be “very tight restrictions” placed on its distribution and it is intended only for supervised settings like hospitals.

Read more

Physics tells us that a hammer and a feather, dropped in a vacuum, will fall at the same rate – as famously demonstrated by an Apollo 15 astronaut on the Moon. Now, CERN scientists are preparing to put a spooky new spin on that experiment, by dropping antimatter in a vacuum chamber to see if gravity affects it the same way it does matter – or if antimatter falls upwards instead.

Read more

Rutgers scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer’s and Parkinson’s diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries.

Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections.

So, Rutgers scientists designed bio-scaffolds that mimic natural tissue and got good results in test tubes and mice, according to a study in Nature Communications. These nano-size scaffolds hold promise for advanced stem cell transplantation and neural tissue engineering. Stem cell therapy leads to stem cells becoming neurons and can restore neural circuits.

Read more

What was it like to see, up close, the H-IIA rocket (that carried Diwata-2) leave the grounds of Japan’s Tanegashima Space Center last October 29? Here’s a firsthand account from BusinessMirror.


WHILE waiting for the launching of Diwata-2 at the view deck in Tanegashima Space Center in Kagoshima, Japan, with our cameras trained at the launch site, Dr. Joel Marciano, the head of Philippine Scientific Earth Observation Microsatellite Program (PHL-Microsat) whispered: “Don’t just look at the rising rocket [named H-IIA F40 that carries Diwata-2] through your camera. Look at the real event so you can feel it.”

I didn’t know and did not have the time to ask what he meant by “feel it.”

But as the countdown started and the rocket began rising into the sky with Diwata-2 on it, I began to understand what Dr. Marciano meant.

The International Space Station is your orbiting laboratory, and the science being conducted there will help us push farther into deep space, while providing benefits back on Earth. Microgravity unlocks new worlds of discovery. Dive into what we’re learning: 🔬🚀.

Read more